Publications
Links to our latest financial and sustainability reports and other recent publications.
Investors
Full-Year 2024 Financial Results
Grifols’ fourth quarter and year-end 2024 results.
Showing 222 search results
Press release
Grifols Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients
Press release
Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029
Press release
Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow
Press release
Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner
Press release
Grifols completes enrollment of second cohort in first-in-human Alpha-1 15% subcutaneous option for treating alpha1-antitrypsin deficiency
Press release
Grifols collaborates with startup FcR Therapeutics to develop recombinant therapies for autoimmune diseases
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.